NR4A1 and breast cancer: The majority of patients with diabetes (497 of 574 patients [86.6%]) and patients without diabetes (1893 of 2155 patients [87.8%]) with hormone receptor-positive breast cancer (2729 patients) initiated endocrine therapy within a year of diagnosis.